DepYmed

Focus: DepYmed is a publicly-traded biotechnology company developing small molecules with copper chelating properties focused on oncology. The company is based in Farmingdale, NY and operates at an early stage with a single Phase 1 program.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About DepYmed

AI assessmentNot Hiring

No open roles listed right now. Follow DepYmed to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MSI-1436C

Metastatic Breast Cancer

PHASE_1

Clinical Trials (1)

NCT02524951Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer

Phase 1

Help build intelligence for DepYmed

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on novel copper chelation mechanism of action in oncology, a differentiated approach with potential IP moat
Public company status provides equity liquidity and established governance structures absent in early-stage private firms
Early-stage pipeline allows for significant individual impact on drug development strategy and scientific direction

Watch Out For

Only one Phase 1 program in development with no marketed products, creating zero near-term revenue visibility and high cash burn risk
Zero active job openings at time of data capture suggests limited hiring or potential financial constraints
Minimal public disclosure on financials, headcount, and recent milestones limits transparency for career planning

Generated by Claude from DepYmed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline